{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"75.000","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"163,428,541","primaryexch":"香港交易所","ric":"2696.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":1.5096,"inline_upper_strike_price":"","sedol":"BKLJK94","am":"70.13","iv":"","ew_strike":"","as":"71.550","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"71.500","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"15.200","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Wenjie Zhang","underlying_ric":"2696.HK","hi52":"92.000","issuer_name":"上海復宏漢霖生物技術股份有限公司 - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"71.250","mkt_cap":"11.69","f_aum_hkd":null,"ew_sub_per_to":"","ls":"71.550","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-2.600","aum":"","issued_shares_class_B":null,"vo":"961.21","secondary_listing_flag":false,"listing_date":"2019年9月25日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"上海復宏漢霖生物技術股份有限公司 - H股","nm_s":"復宏漢霖","sym":"2696","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"上海復宏漢霖生物技術股份有限公司是一家主要從事生物製藥研發、生物製藥服務及生物製藥生產與銷售的中國公司。該公司的主要產品包括漢曲優（註射用曲妥珠單抗）、漢奈佳（馬來酸奈拉替尼片）、漢斯狀（斯魯利單抗註射液）、漢利康（利妥昔單抗註射液）、漢達遠（阿達木單抗註射液）、漢貝泰（貝伐珠單抗註射液）等。該公司的產品主要應用於乳腺癌輔助治療、轉移性乳腺癌及轉移性胃癌治療、轉移性非鱗狀非小細胞肺癌、多關節型幼年特發性關節炎治療等。該公司主要在中國國內和海外市場開展業務。","op":"74.150","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國<br/>中國（上海）自由貿易試驗區<br/>張衡路1999號<br/>7座303、304室","pc":"-3.51","days_to_expiry":null,"underlying_code":null,"pe":"44.73","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"74.150","isin":"CNE100003N76","moneyness":""}},"qid":"1759074179318"}
